Oppenheimer Maintains Outperform on CME Gr, Raises Price Target to $245
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Owen Lau has maintained an 'Outperform' rating on CME Group (NASDAQ:CME) and raised the price target from $228 to $245.
October 14, 2024 | 3:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has reaffirmed its 'Outperform' rating for CME Group and increased the price target to $245, indicating a positive outlook.
The increase in price target from $228 to $245 by Oppenheimer suggests a positive outlook for CME Group, likely leading to a short-term increase in stock price as investors react to the analyst's confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100